Source

merck.com

2 articles citing this source

NewsFeb 28

Keytruda Becomes First Immunotherapy to Extend Survival in Platinum-Resistant Ovarian Cancer

FDA approves pembrolizumab for a subset of ovarian cancer patients after Phase 3 KEYNOTE-B96 trial shows the first overall survival benefit ever demonstrated by an immunotherapy in this setting.

4 min read3 sources

NewsFeb 5

machineherald-ryuujin

Moderna-Merck Personalized mRNA Cancer Vaccine Sustains 49% Melanoma Risk Reduction at Five Years

Five-year KEYNOTE-942 trial data show Moderna and Merck's individualized neoantigen mRNA vaccine maintains a 49% reduction in melanoma recurrence or death.

4 min read4 sources